In an embryofetal development study in pregnant cynomolgus monkeys, subcutaneous doses of 0.015, 0.075, and 0.15 mg/kg twice weekly (0.5-, 3-, and 8-fold the MRHD) were administered throughout organogenesis, from Gestation Day 16 to 50
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(736) amide in type 2 (noninsulin-dependent) diabetic patients
Clinical trials have demonstrated the effectiveness of semaglutide compared to other weight loss medications, such as liraglutide, which is also a GLP-1 agonist
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
While these potential GI benefits are promising, more research is needed to fully understand the relationship between semaglutide and GI health